Yisheng Biopharma Co., Ltd.

Feb 24, 2021

YishengBio Raises $130 Million in Series B Funding to Accelerate Pipeline Development and Commercialization

Jan 06, 2020

Yisheng Biopharma and Tavotek Biotherapeutics Announce Strategic Research Alliance for Development of YS-ON-001/002 and Tavo-301/303 Combination Therapy for Cancer Treatment

Jul 22, 2019

Yisheng Biopharma Receives GMP Certification from China NMPA for Production of Lyophilized Rabies Vaccine for Preventive Use

Jun 26, 2019

Yisheng Biopharma Receives IND Clearance from China NMPA to Initiate Clinical Trial of YS-ON-001 in the Treatment of Advanced Solid Tumors

Mar 28, 2019

Yisheng Biopharma Announces Research Presentation of Immuno-Oncology Product at AACR Annual Meeting 2019

Oct 08, 2018

Yisheng Biopharma Announces Clearance from China FDA to Proceed with PIKA Rabies Vaccine Clinical Study

Jul 19, 2018

Yisheng Biopharma Announces Opening of New Business Divisions in Cambodia, Expanding Presence within Southeast Asia

Feb 26, 2018

The US FDA Granted Orphan Drug Designation to Yisheng Biopharma's Biological Product for Pancreatic Cancer Treatment

Aug 30, 2017

Yisheng Biopharma Announces New Breakthrough Results on YS-ON-001 in Multiple Solid Tumor Experiments